Abstract:Glioblastoma (GBM), the most common primary brain tumor in adults, comprises all WHO Grade IV gliomas of astrocytic origin. Despite extensive characterization of the molecular and genetic features of GBM, there remains a paucity of viable treatment options, and this disease confers a dismal 5% 5-year survival rate. Genomic amplification of epidermal growth factor receptor (EGFR) occurs in 40-60% of primary GBM. Half of all EGFR-amplified cases of GBM also harbor EGFRvIII, a constitutively active, truncated variant of EGFR. EGFR and EGFRvIII transduce oncogenic signals via cytoplasmic mediators, including the JAK/STAT signal transduction pathway. The oncogenic role of STAT3 has been well-studied in CNS malignancies; STAT3 has been found to induce the expression of target genes involved in the proliferative and invasive phenotypes of GBM. However, little is known about the mechanism and role of STAT5 activation in GBM progression. Microenvironmental cues and EGFRvIII signaling, lost in adherent cell culture, are required for STAT5 activation, making STAT5 difficult to study by conventional cell culture methods. Our recent data from patient-derived xenograft (PDX) cultures demonstrates that activation of STAT5 is important in GBM cell invasion and survival. Further, STAT5 activation is present predominantly at the invasive periphery of the tumor. In this study, we seek to characterize the mechanism and role of STAT5 activation downstream of EGFRvIII in GBM. RNA sequencing of PDX tumors expressing stable shRNA knockdown of STAT3 or STAT5 indicate both redundant and distinct transcriptional changes induced by STAT3 and STAT5 in GBM. We also find that while STAT3 activation is dependent upon JAK1/2, STAT5 activation is JAK-independent downstream of EGFRvIII in GBM. Depletion of JAK1/2 expression by siRNA oligonucleotides and pharmacologic inhibition of JAK1/2 suppressed STAT3 activation but not STAT5. In fact, targeting JAK2 with kinase inhibitor WP1066 suppressed STAT3 activation, but increased activation of STAT5 in GBM cells expressing EGFR/EGFRvIII. Inhibition of Src family kinases (SFK), a family of upstream signaling effectors of the JAK/STAT pathway, attenuates both STAT3 and STAT5 activation. These results suggest that activation of STAT5 may provide a therapeutic escape mechanism to JAK-STAT3 inhibition in GBM, necessitating dual STAT3 and STAT5 inhibition to successfully inhibit the distinct oncogenic signals transmitted by STAT3 and STAT5 to promote GBM cell survival and resistance. Citation Format: Mylan Blomquist, Serdar Tuncali, Christopher Sereduk, Jean Kloss, Joseph Loftus, Nhan Tran. JAK-independent STAT5 signaling as a node of therapeutic vulnerability in glioblastoma [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 101.

Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3.

STEM-43. GSK3β PROMOTES THE BMX-MEDIATED STAT3 ACTIVATION TO MAINTAIN GLIOBLASTOMA STEM CELLS

Ibrutinib Inactivates BMX-STAT3 in Glioma Stem Cells to Impair Malignant Growth and Radioresistance.

HDAC7 Drives Glioblastoma to a Mesenchymal-Like State Via LGALS3-mediated Crosstalk Between Cancer Cells and Macrophages

BMX-ARHGAP fusion protein maintains the tumorigenicity of gastric cancer stem cells by activating the JAK/STAT3 signaling pathway

Abstract 2099: FoxM1 Drives a Feed-Forward STAT3-activation Signaling Loop to Promote the Self-Renewal and Tumorigenicity of Glioblastoma Stem Cells

Abstract 101: JAK-independent STAT5 signaling as a node of therapeutic vulnerability in glioblastoma

BMX/Etk Promotes Cell Proliferation and Tumorigenicity of Cervical Cancer Cells Through PI3K/AKT/mTOR and STAT3 Pathways

CBX3 accelerates the malignant progression of glioblastoma multiforme by stabilizing EGFR expression

Tetraspanin CD9 Stabilizes Gp130 by Preventing Its Ubiquitin-Dependent Lysosomal Degradation to Promote STAT3 Activation in Glioma Stem Cells

High SOX9 Maintains Glioma Stem Cell Activity through a Regulatory Loop Involving STAT3 and PML

The Zinc Finger Transcription Factor Zfx is Required for Maintaining the Tumorigenic Potential of Glioblastoma Stem Cells

GSK3 Palmitoylation Mediated by ZDHHC4 Promotes Tumorigenicity of Glioblastoma Stem Cells in Temozolomide-Resistant Glioblastoma Through the EZH2-STAT3 Axis

Effect of A Small Molecule Inhibitor of the Jak2/Stat3 Pathway on Self-Renewal of Glioblastoma Stem Cells

SH2B3, Transcribed by STAT1, Promotes Glioblastoma Progression Through Transducing IL-6/gp130 Signaling to Activate STAT3 Signaling

Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.

Knockdown of STAT3 Expression by RNAi Suppresses Growth and Induces Apoptosis and Differentiation in Glioblastoma Stem Cells.

Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells.

A Noval STAT3 Pathway Inhibitor Suppresses the Self-renewal and Induces Apoptosis in Glioblastoma Stem Cells

Signal Transducer and Activator of Transcription 3 Promotes Angiogenesis and Drives Malignant Progression in Glioma

The role of STAT3 activation in modulating the immune microenvironment of GBM